These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26142874)

  • 1. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
    Cella CA; Minucci S; Spada F; Galdy S; Elgendy M; Ravenda PS; Zampino MG; Murgioni S; Fazio N
    Cancer Treat Rev; 2015 Nov; 41(9):754-60. PubMed ID: 26142874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J; Kulke M
    Curr Treat Options Oncol; 2014 Sep; 15(3):365-79. PubMed ID: 25092520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
    Yim KL
    Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK; Bergsland EK
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.
    Phan AT; Dave B
    Cancer Med; 2016 Oct; 5(10):2953-2964. PubMed ID: 27539383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
    Vicier C; Dieci MV; Andre F
    Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG; Strosberg JR; Halfdanarson TR
    Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
    Lamberti G; Brighi N; Maggio I; Manuzzi L; Peterle C; Ambrosini V; Ricci C; Casadei R; Campana D
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29509701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
    Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
    Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
    Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.
    Salazar R; Reidy-Lagunes D; Yao J
    Drugs; 2011 May; 71(7):841-52. PubMed ID: 21568362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
    Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
    Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors.
    Capdevila J; Salazar R; Halperín I; Abad A; Yao JC
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():27-34. PubMed ID: 21311955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.